November 23, 2011

SEBIO Announces Winners of Regional Deal of the Year Awards

Filed under: SEBIO News — admin @ 12:04 pm

Atlanta, GA - The winners of Southeast BIO’s (SEBIO) Southeast Deal of the Year awards were announced in a ceremony held at its 13th Annual Investor Forum in Durham, North Carolina on November 3rd. Companies honored at the fifth annual awards ceremony competed in the following categories:

• Initial Funding
• Venture Capital Transaction
• Strategic Transaction
• Strategic Investment

The winners were Sebacia, Inc., Chimerix, Inc., ArtusLabs, and Liquidia Technologies. (more…)

November 17, 2011

Pandora Genomics LLC wins seed-capital contest

Filed under: Regional Venture News — admin @ 9:59 am

ORLANDO, FL - A Central Florida initiative to support local entrepreneurs has selected two high-technology companies as the winners of its first $200,000 seed-capital sweepstakes.

The Florida IDEA Grant Program chose Pandora Genomics LLC of Orlando and Rillip Inc. of Edgewater to receive grants of as much as $50,000 each.

The companies — one a biotech startup, the other an online data-mining firm — will also receive in-kind services such as accounting, marketing and legal assistance valued at as much as $50,000 each, program officials said this week.
(more…)

November 14, 2011

13th Annual SEBIO Investor Forum a Huge Success

Filed under: SEBIO News — admin @ 6:34 pm

ATLANTA, GA - Nearly 400 people attended Southeast BIO’s (SEBIO) Thirteenth Annual Investor Forum, the region’s premier life sciences conference, held on November 2-3, 2011. Venture capitalists and angel investors connected with executives, life science entrepreneurs, university representatives and industry professionals in Durham, North Carolina to discuss opportunities for growth of the life sciences industry in the coming years.

“SEBIO continues to be the forum that draws all of the key members of the Southeast’s life science ecosystem: investors, entrepreneurs, technology transfer professionals and the life science business community come together in support of companies from across the Southeast,” said Aaron Davidson, Managing Director of H.I.G. Capital, Co-Head of H.I.G. BioVentures and newly elected Chair of SEBIO. “The Investor Forum provides a very efficient opportunity for the emerging leaders of tomorrow’s biopharmaceutical, medical technology and diagnostic companies to network with the other leaders of our ecosystem.”

Fred Eshelman, Founder and Executive Chairman of PPD, kicked off the two-day “Data Driven Deals” event by sharing highlights of his 20 year voyage of taking PPD from a one person start-up to the $3.9 billion buyout offer.

Jim Mullen, CEO of Patheon, closed the conference by offering his insights on how today’s pressures on the big pharma business model will impact cost structures in the future. The attendees were given a treat when North Carolina State Treasurer Janet Cowell unveiled the $35 million “Accelerator” investment fund, targeted for life sciences start-ups, at the event’s closing luncheon.

Twenty-eight of the most promising life sciences companies in the Southeast presented their funding pitches to representatives of more than 30 venture funds from across the U.S. The more advanced companies who have completed at least one round of institutional financing presented on the SEBIO MAIN/Stage. Twenty of the companies, as participants in the EARLY/Stage program or BIO/Plan Competition, were the beneficiaries of expert mentoring from teams made up of active venture capitalists and angel investors, entrepreneurs and managers, and service providers with relevant start-up expertise.

The EARLY/Stage program, geared for the best new initial investment opportunities in the region, allowed participants to introduce their companies to and seek advice from onsite advisory teams, who then chose the four best to participate in the EARLY/Stage Company Shootout on November 2. The selected participants were Arbovax, Inc. (Raleigh, NC), Claro Scientific, LLC (St. Petersburg, FL), Clinical Sensors, Inc. (Chapel Hill, NC) and NellOne Therapeutics, Inc. (Oak Ridge, TN).

Claro Scientific, LLC was selected as the winner of the EARLY/Stage Shootout by a panel of celebrity judges representing four venture capital funds. Claro Scientific is developing a portable, low cost, real time point of care diagnostic system for medical and research applications. The members of the Claro Scientific management team include Thomas McLain, CEO, and Luis Garcia-Rubio, President and CSO.

SEBIO also announced the winner of its fifth annual BIO/Plan Competition, which brings forward some of the most promising new technologies from the region’s research organizations. Four final competitors (CureSwitch, LLC, University of Florida; Infusense, LLC, University of Tennessee Health Science Center; Transcatheter Valve Technologies, Emory University; and ViaMune, Inc., University of Georgia) were selected from ten semifinalists who underwent a rigorous mentoring process over the past four months to develop an executable business strategy and associated written development plan.

The winner of the 2011 BIO/Plan Competition is Transcatheter Valve Technologies (TVT), a project developed at Emory University in Atlanta, Georgia. TVT is a percutaneous mitral valve replacement technology. The principals associated with TVT include Muralidhar Padala, Inventor, and James Greene, Industry Consultant.

The winning TVT mentoring team includes Bob Crutchfield, Harbert Venture Partners, John Perchorowicz, Triage Masters, and Harold Shlevin, Enterprise Innovation Institute at Georgia Tech.

The 2012 Southeast BIO Investor Forum will be held October 31 – November 1, 2012 at the Breakers Resort in Palm Beach, Florida. Further details will be posted on the SEBIO website (www.sebio.org).

November 9, 2011

Salix Pharmaceuticals to Acquire Oceana Therapeutics

Filed under: Other Regional News — admin @ 10:24 am

RALEIGH, NC - Salix Pharmaceuticals, Ltd. and Oceana Therapeutics, LLC today announced that they have entered into a definitive agreement whereby Salix will acquire all of the outstanding stock of Oceana Therapeutics, Inc., a privately–held global provider of gastroenterology and urology therapeutics, for $300 million in cash. The transaction is subject to customary conditions to closing, including U.S. anti–trust approval, and is expected to close in December 2011.
(more…)

RxBio nabs $15 million federal contract for anti-radiation drug development

Filed under: Other Regional News — admin @ 10:17 am

JOHNSON CITY, TN - RxBio Inc. has received a $15 million federal contract from a U.S. Department of Health and Human Services ’ entity that will allow the company to continue development of its anti-radiation drug Rx100.

If the development is successful, Rx100 will be available to be administered up to 72 hours after acute radiation exposure. Other radiation treatment drugs have to be administered 24 hours after exposure. According to a company statement, no drug that can be administered in that time frame has been approved by the U.S. Food and Drug Administration. The contract’s base is $15 million, but it could be worth as much as $24 million for the company in the next two years.
(more…)

November 7, 2011

Accentia has $10 million deal to sell Analytica

Filed under: Other Regional News — admin @ 3:43 pm

TAMPA, FL - Accentia Biopharmaceuticals Inc. agreed to sell the assets of its Analytica International Inc. business unit for up to $10 million to LA-SER Alpha Group Sarl.

The sale is part of a series of deals Accentia plans to strengthen its financial position, improve its balance sheet and support ongoing biotech development plans, a company statement said.
(more…)

Ancor buys WellSpring Pharmaceutical

Filed under: Other Regional News — admin @ 3:39 pm

SARASOTA, FL - Ancor Capital Partners acquired WellSpring Pharmaceutical Corp.WellSpring, based in Sarasota and in Toronto, is a manufacturer and marketer of specialty prescription and over-the-counter products, and offers contract manufacturing.

Financial terms of the acquisition were not disclosed in a statement announcing the deal.
(more…)

November 4, 2011

N.C. ‘Accelerator’ to invest $35M in early-stage life science companies

Filed under: Regional Venture News — admin @ 12:13 pm

RALEIGH, NC - Early-stage life science companies have long grumbled about the ability to secure financing and those grumbles have only grown louder given the market conditions that have dried up many financing options.The state of North Carolina will now provide another way for life science companies to slake their thirst for capital. State Treasurer Janet Cowell will invest up to $35 million from the state’s pension fund to support early-stage life science companies in the state. Cowell formally announced the “Accelerator” at the Southeast BIO Investor Forum in Durham, North Carolina today.
(more…)